 |
|
|
| |
PEGINTERFERON LAMBDA-1a(LAMBDA) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGINTERFERON ALFA-2a(ALFA-2a) IN PATIENTS WITH CHRONIC HCV INFECTION (G1/2/3/4): EMERGE PHASE 2bTHROUGH WEEK 12RESULTS
|
| |
| |
Reported by Jules Levin
<
The 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei International ConventionCenter, February 16-19, 2012
<
RODRIGUEZ-TORRES M,1ISHAK L,2FONTANA D,2XU D,3GRAY T,2HORGA A,3HILLSON J,2ZEUZEM S,4LOPEZ-TALAVERA JC,3FOR THE EMERGE STUDY GROUP1FUNDACION DE INVESTIGACION, SAN JUAN, PUERTO RICO; 2ZYMOGENETICS/BMS, SEATTLE, WA, USA; 3BRISTOL-MYERS SQUIBB, WALLINGFORD, CT, USA; 4KLINIKUM DER JOHANN-WOLFGANG GOETHE-UNIVERSITAT, FRANKFURT/MAIN, GERMANY
|
| |
|
|
|
|
|
